Irbesartan Dosing
For hypertension, initiate irbesartan at 150 mg once daily and titrate to 300 mg once daily as needed; for diabetic nephropathy in type 2 diabetes, use 300 mg once daily; reduce the starting dose to 75 mg once daily in volume-depleted patients; and discontinue irbesartan immediately in pregnancy. 1
Standard Dosing Regimens
Hypertension
- Initial dose: 150 mg once daily 1
- Titration: May increase to maximum dose of 300 mg once daily as needed for blood pressure control 1
- Administration: Can be taken with or without food and may be combined with other antihypertensive agents 1
- Onset of effect: Blood pressure reduction is apparent after the first dose, with near-maximal effect achieved by 2 weeks 1
- Duration: Provides 24-hour blood pressure control with once-daily dosing, with trough-to-peak ratios of 60-70% 1
Diabetic Nephropathy in Type 2 Diabetes
- Recommended dose: 300 mg once daily 1
- Indication: For hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria 2, 3
- Renoprotective benefit: Irbesartan 300 mg reduces progression to overt nephropathy by 70% compared to placebo in patients with microalbuminuria 4
- Independent effect: The renoprotective benefit is partly independent of blood pressure lowering 3
Special Population Adjustments
Volume or Salt Depletion
- Initial dose: 75 mg once daily 1
- Applicable to: Patients treated vigorously with diuretics or on hemodialysis 1
- Rationale: Reduces risk of symptomatic hypotension in volume-depleted states 1
Renal Impairment
- Mild to moderate impairment (eGFR 30-79 mL/min/1.73 m²): No dose adjustment required 5
- Severe impairment (eGFR <30 mL/min/1.73 m²): Use with caution; irbesartan can be used but requires close monitoring 5
- Continuation with declining function: May continue irbesartan as eGFR declines below 30 mL/min/1.73 m² for cardiovascular benefit without significantly increasing risk of end-stage kidney disease 6
- Monitoring: Check serum creatinine and potassium within 7-14 days after initiation and at least annually 6
Hepatic Impairment
- Mild impairment (Child-Pugh A): No dose adjustment required 5
- Moderate impairment (Child-Pugh B): Use with caution; no specific dose adjustment in FDA labeling, though general caution advised 5
- Severe impairment (Child-Pugh C): Avoid use 5
Pregnancy
- Absolute contraindication: Discontinue immediately upon pregnancy recognition 7, 6, 8
- Mechanism of harm: Causes fetal renal dysplasia, oligohydramnios, pulmonary hypoplasia, and intrauterine growth restriction 8
- Preconception planning: Switch to pregnancy-safe alternatives (methyldopa, labetalol, long-acting nifedipine) before conception in women of childbearing potential 7, 8
- First trimester exposure: While first trimester ACE inhibitor exposure may not be associated with congenital malformations, ARBs should be stopped as soon as possible to avoid second and third trimester fetopathy 8
Clinical Context and Monitoring
Diabetic Nephropathy Considerations
- Albuminuria categories: For UACR ≥300 mg/g, irbesartan or another ACE inhibitor/ARB is strongly recommended as first-line therapy 9, 6
- Moderate albuminuria (UACR 30-299 mg/g): ACE inhibitor or ARB is suggested, though evidence is weaker 9, 7
- Normal albuminuria: ACE inhibitors/ARBs not superior to other antihypertensive classes for cardioprotection 7
- Ultrahigh dosing: Irbesartan 900 mg once daily provides additional 15% reduction in albuminuria compared to 300 mg, particularly in patients with higher baseline albuminuria, though this is not FDA-approved 10
Important Contraindications and Cautions
- Dual RAS blockade: Never combine with ACE inhibitors, other ARBs, or direct renin inhibitors—increases hyperkalemia and acute kidney injury risk without additional benefit 7, 6, 11
- Bilateral renal artery stenosis: May cause rapid decline in renal function 12
- Hyperkalemia monitoring: Essential when used with other agents affecting potassium, especially in CKD 9, 6